Early immune response to the largely used Mycobacterium bovis bacillus Calmette-Guérin (BCG) intradermal vaccine remains ill defined. Three days after BCG inoculation into the mouse ear, in addition to neutrophils infiltrating skin, we observed CD11b(+)Ly-6C(int)Ly-6G(-) myeloid cells. Neutrophil depletion markedly enhanced their recruitment. These cells differed from inflammatory monocytes and...

OBJECTIVE To describe a case of epididymo-orchitis that developed four years after treatment with intravesical bacillus Calmette-Guérin (BCG) and to review the incidence of this adverse effect. DATA SOURCES Information about the patient was obtained from the medical chart. A MEDLINE search of English-language literature (from January 1976 to April 1999) was conducted. STUDY SELECTION All ca...

A possible correlation between the impact of Covid-19 and universal immunization program against tuberculosis with Bacillus Calmette-Guérin (BCG) vaccine was suggested previously, based on apparent lower epidemics a record national BCG program. In this work time-adjusted dataset statistical data by subnational health jurisdictions at time point six months after local arrival used to perform ana...

conclusions results showed that hcvcp + bcg induced a moderate ctl and mixed th1/th2 immune responses with higher levels of cell proliferation and ifn-γ secretion, indicating that bcg may have a better outcome when formulated in hcvcp-based subunit vaccines. results expression and purification of core protein around the expected size (21 kda) was confirmed by western blotting. the hcvcp + bcg v...

Cancer is one of the most common families diseases today with millions new patients every year around world. Bladder cancer (BC) prevalent types affecting both genders, and it not known to be associated a specific group in population. The current treatment standard for BC follows weekly Bacillus Calmette–Guérin (BCG) immunotherapy-based therapy protocol which includes BCG IL-2 injections. Unfor...

Abstract Background The paper aimed to analyze and evaluate the present literature data on clinical effectiveness of using bacillus Calmette–Guérin (BCG) vaccine in protecting against novel coronavirus disease 2019 (COVID-19). Main body Several have shown a relationship between vaccinated population with severity mortality rate from However, linkage BCG COVID-19 infection morbidity is still amb...

Bacillus Calmette-Guérin (BCG) remains the most effective intravesical therapy for non-muscle invasive bladder cancer but will fail in up to 40% of patients. The ability to identify patients who are least likely to respond to further BCG therapy allows urologists to pursue secondary treatments more likely to convey a recurrence or survival benefit to the patient. We examined the literature to d...

Screening for active tuberculosis (TB) and latent TB infection (LTBI) is mandatory prior to the initiation of tumour necrosis factor-alpha inhibitor therapy. However, no agreement exists on the best strategy for detecting LTBI in this population. The aim of the present study was to analyse the performance of the tuberculin skin test (TST) and QuantiFERON-TB Gold in-tube (QFT-GIT) on LTBI detect...

BACKGROUND Intravesical instillation of Bacillus Calmette-Guérin (BCG) is the treatment of choice for superficial bladder carcinoma. Complications of BCG therapy include local infections and disseminated BCG infection with multiple endorgan complications. CASE PRESENTATION We report a case of disseminated, post-treatment BCG infection that initially presented with granulomatous hepatitis and ...